RESEARCH OF SUBCHRONIC TOXICITY IN RATS OF GLYCOSIDE DERIVATIVE OF INDOLOCARBAZOLE LCS-1208

Background. In N.N. Blokhin Russian Cancer Research Center has been developed injectable dosage form based on the substance of indolocarbazole derivative LCS-1208, studied its antitumor activity and mechanism of antitumor effect, which was the basis for the pre-clinical study of the drug toxicity. Objective. The study of subchronic toxicity of formulation of glycoside derivative of indolocarbazole - LCS-1208 after intraperitoneal application to rats. Materials and methods. Dosage form of study drug: lyophilisate for preparation of solution for injection of 9,0 mg in vial. The study was conducted on 40 healthy non inbred male rats, which were obtained from the breeding of the N.N. Blokhin Russian Cancer Research Center. It was studied the action of the drug on the peripheral blood, the functional state of the liver, kidney and gastrointestinal tract of animals. Results. The drug LCS-1208 by daily intraperitoneal administration to rats for 15 days in the 3 studied doses (total dose 200 mg/kg, 100 mg/kg and 50 mg/kg) did not cause death of animals, had no effect on the general condition of the animals, did not cause external manifestations of toxicity, did not change behavioral responses of animals and had no effect on the functioning of the studied organs. Conclusion. The results obtained by the study of the subchronic toxicity in rats were the basis for further preclinical toxicology study of the drug LCS-1208.

субхроническая токсичность, производные индолокарбазола, ЛХС-1208, subchronic toxicity, derivatives of indolocarbazole, LCS-1208

1. Meng L.-H., Liao Z.-Y., Pommier Y. Non-camptothecin DNK topoisomerase I inhibitors in cancer therapy. Curr Top Med Chem 2003; 3(3): 305-20. PMID: 12570765.

2. Sordet O., Khan Q.A., Kohn K.W., Pommier Y. Apoptosis induced by topoisomerase inhibitors. Curr Med Chem Anticancer Agents 2003; 3(4): 271-90. PMID: 12769773.

3. Civenni G., Longoni N., Costales P. et al. EC-70124, a novel glycosylated indolocarbazole multikinase inhibitor, reverts tumori-genic and stem cell properties in prostate cancer by inhibiting STAT3 and NF-kB. Mol Cancer Ther 2016; 15(5): 806-18. D0I: 10.1158/1535-7163. MCT-15-079. PMID: 26826115.

4. El Sayed M.T., Ahmed K.M., Mahmoud K., Hilgeroth A. Synthesis, cytostatic evaluation and structure activity relationships of novel bis-indolylmethanes and their corresponding tetrahydroindolocarbazoles. Eur J Med Chem 2015; 90: 845-59. DOI: 10.1016/j.ejmech.2014.12.008. PMID: 25528338.

5. Sherer C., Snape T.J. Heterocyclic scaffolds as promising anticancer agents against tumours of the central nervous system: exploring the scope of indole and carbazole derivatives. Eur J Med Chem 2015; 97: 552-60. DOI: 10.1016/j.ejmech.2014.11.007. PMID: 25466446.

6. Singh S., Kim Y., Wang F. et al. Structural characterization of AtmS13, a putative sugar aminotransferase involved in indolocarbazole AT2433 aminopentose biosynthesis. Proteins 2015; 83(8): 1547-54. DOI: 10.1002/prot.24844. PMID: 26061967.

7. Yoshida A., Ookura M., Zokumasu K., Ueda T. Gö6976, a FLT3 kinase inhibitor, exerts potent cytotoxic activity against acute leukemia via inhibition of survivin and MCL-1. Biochem Pharmacol 2014; 90(1): 16-24. DOI: 10.1016/j.bcp. 2014.04.002. PMID: 24735609.

8. Ланцова А.В., Санарова Е.В., Оборотова Н.А. и др. Разработка технологии получения инъекционной лекарственной формы на основе отечественной субстанции производной индолокарбазола - ЛХС-1208. Российский биотерапевтический журнал 2014; 12(3): 25-32.

9. Киселева М.П., Шпрах З.С., Борисова Л.М. и др. Доклиническое изучение противоопухолевой активности производного N-гликозида индолокарбазола ЛХС-1208. Сообщение I. Российский биотерапевтический журнал 2015; 14(2): 71-7.

10. Киселева М.П., Шпрах З.С., Борисова Л.М. и др. Доклиническое изучение противоопухолевой активности производного N-гликозида индолокарбазола ЛХС-1208. Сообщение II. Российский биотерапевтический журнал 2015; 14(3): 41-7.

11. Николина А.А., Кульбачевская Н.Ю., Коняева О.И. и др. Изучение острой токсичности нового противоопухолевого лекарственного средства на основе производного индолокарбазола - ЛХС-1208. Российский биотерапевтический журнал 2015; 14(4): 59-64.

12. Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. Под ред. Р.У. Хабриева. М., 2005. C. 170-203.